Published in J Clin Invest on January 01, 2010
Clonal evolution in cancer. Nature (2012) 11.07
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol (2010) 4.22
Single-cell sequencing-based technologies will revolutionize whole-organism science. Nat Rev Genet (2013) 4.03
Development and applications of single-cell transcriptome analysis. Nat Methods (2011) 2.62
Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol (2010) 2.15
The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia (2010) 2.12
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell (2011) 2.04
Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat (2010) 1.98
Controlling escape from angiogenesis inhibitors. Nat Rev Cancer (2012) 1.81
Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol (2012) 1.75
Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat Rev Urol (2012) 1.73
Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev (2012) 1.64
VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res (2011) 1.62
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61
The in vitro spheroid melanoma cell culture assay: cues on tumor initiation? J Invest Dermatol (2010) 1.53
Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression. Cell Tissue Res (2011) 1.53
EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget (2010) 1.53
Obesity and cancer--mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol (2014) 1.51
Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol (2012) 1.50
Cancer stem cells in glioblastoma--molecular signaling and therapeutic targeting. Protein Cell (2010) 1.45
Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells. J Invest Dermatol (2015) 1.43
Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest (2012) 1.37
Stem cells: roadmap to the clinic. J Clin Invest (2010) 1.27
The spatial distribution of LGR5+ cells correlates with gastric cancer progression. PLoS One (2012) 1.26
Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol (2012) 1.24
Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol (2012) 1.24
ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res (2011) 1.23
Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl Med (2012) 1.22
Drug rechallenge and treatment beyond progression--implications for drug resistance. Nat Rev Clin Oncol (2013) 1.22
Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology (2011) 1.22
"Persisters": survival at the cellular level. PLoS Pathog (2011) 1.19
Frizzled7 as an emerging target for cancer therapy. Cell Signal (2011) 1.16
Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. PLoS One (2011) 1.16
Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun (2010) 1.13
Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. Cancer Res (2012) 1.13
Tumor-initiating and -propagating cells: cells that we would like to identify and control. Neoplasia (2010) 1.11
Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses. EMBO Mol Med (2013) 1.04
Genotypic and phenotypic characterization of side population of gastric cancer cell lines. Am J Pathol (2011) 1.03
Cancer stem-like cells in Epstein-Barr virus-associated nasopharyngeal carcinoma. Chin J Cancer (2014) 1.02
MicroRNAs in colorectal carcinoma - from pathogenesis to therapy. J Exp Clin Cancer Res (2016) 1.00
Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. EMBO Mol Med (2010) 0.98
Cancer stem cell markers in head and neck squamous cell carcinoma. Stem Cells Int (2013) 0.97
C8orf4 negatively regulates self-renewal of liver cancer stem cells via suppression of NOTCH2 signalling. Nat Commun (2015) 0.97
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol (2015) 0.96
Colon cancer stem cells: controversies and perspectives. World J Gastroenterol (2013) 0.95
Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Invest (2013) 0.94
PBX3 is targeted by multiple miRNAs and is essential for liver tumour-initiating cells. Nat Commun (2015) 0.94
ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Res (2014) 0.94
Understanding tumor heterogeneity as functional compartments--superorganisms revisited. J Transl Med (2011) 0.93
Advanced prostate cancer--a case for adjuvant differentiation therapy. Nat Rev Urol (2012) 0.93
MicroRNAs in pancreatic ductal adenocarcinoma. World J Gastroenterol (2011) 0.93
Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer. Oncotarget (2015) 0.93
Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther (2016) 0.93
MicroRNA: potential targets for the development of novel drugs? Drugs R D (2010) 0.92
Cancer stem cells: repair gone awry? J Oncol (2010) 0.92
Ceramide glycosylation by glucosylceramide synthase selectively maintains the properties of breast cancer stem cells. J Biol Chem (2012) 0.92
Enhanced enrichment of prostate cancer stem-like cells with miniaturized 3D culture in liquid core-hydrogel shell microcapsules. Biomaterials (2014) 0.91
Functional ion channels in stem cells. World J Stem Cells (2011) 0.91
Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy. J Hematol Oncol (2013) 0.91
Autophagy in Cancer Stem Cells: A Potential Link Between Chemoresistance, Recurrence, and Metastasis. Biores Open Access (2015) 0.91
Inhibiting galectin-1 reduces murine lung metastasis with increased CD4(+) and CD8 (+) T cells and reduced cancer cell adherence. Clin Exp Metastasis (2012) 0.91
Stem cells and targeted approaches to melanoma cure. Mol Aspects Med (2013) 0.90
Hurdles in anticancer drug development from a regulatory perspective. Nat Rev Clin Oncol (2012) 0.90
Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. Cancer Med (2013) 0.90
Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives. World J Gastroenterol (2014) 0.90
Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther (2012) 0.89
Stem cells, colorectal cancer and cancer stem cell markers correlations. Curr Health Sci J (2014) 0.89
Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres. Cancer Biol Ther (2012) 0.89
The role of CD95 and CD95 ligand in cancer. Cell Death Differ (2015) 0.88
CD44 and HCELL: preventing hematogenous metastasis at step 1. FEBS Lett (2011) 0.88
The stemness phenotype model. ISRN Oncol (2012) 0.88
Tumor initiation in human malignant melanoma and potential cancer therapies. Anticancer Agents Med Chem (2010) 0.88
Expression of stemness genes in primary breast cancer tissues: the role of SOX2 as a prognostic marker for detection of early recurrence. Oncotarget (2014) 0.87
miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/ tumor initiating cell properties. Oncotarget (2015) 0.87
Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget (2016) 0.86
Eradicating cancer cells: struggle with a chameleon. Oncotarget (2011) 0.86
Genetically determined ABCB5 functionality correlates with pigmentation phenotype and melanoma risk. Biochem Biophys Res Commun (2013) 0.86
EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loop. Oncogene (2015) 0.86
Apoptotic death of cancer stem cells for cancer therapy. Int J Mol Sci (2014) 0.86
Cancer Stem Cell Plasticity Drives Therapeutic Resistance. Cancers (Basel) (2016) 0.86
Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases. Oncotarget (2015) 0.84
Ovarian cancer stem-like cells show induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor. Oncotarget (2013) 0.84
Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment. PLoS One (2011) 0.84
Sca1⁺ murine pituitary adenoma cells show tumor-growth advantage. Endocr Relat Cancer (2014) 0.83
Cancer-associated Fibroblasts Promote Irradiated Cancer Cell Recovery Through Autophagy. EBioMedicine (2017) 0.83
Treatment of breast cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Ther (2012) 0.83
Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors. PLoS One (2011) 0.83
Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Cell Death Dis (2015) 0.82
Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells. Sci Rep (2015) 0.82
Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. J Exp Clin Cancer Res (2013) 0.82
Targeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cells. Cell Death Differ (2014) 0.82
Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells? Clin Exp Metastasis (2013) 0.82
Pancreatic cancer tumour initiating cells: the molecular regulation and therapeutic values. J Cell Mol Med (2012) 0.82
MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. Oncogene (2014) 0.81
N-cadherin impedes proliferation of the multiple myeloma cancer stem cells. Am J Blood Res (2013) 0.81
Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice. Biomed Res Int (2014) 0.81
Down-regulation of the Lamin A/C in neuroblastoma triggers the expansion of tumor initiating cells. Oncotarget (2015) 0.81
Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase. Sci Rep (2015) 0.81
The hallmarks of cancer. Cell (2000) 113.05
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
The epigenomics of cancer. Cell (2007) 30.91
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2006) 24.52
Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Mechanisms of angiogenesis. Nature (1997) 18.04
Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res (2006) 17.42
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 14.87
let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell (2007) 13.69
Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A (2007) 13.58
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell (2009) 12.96
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A (2007) 11.94
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 11.86
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (2004) 11.77
Crypt stem cells as the cells-of-origin of intestinal cancer. Nature (2008) 11.66
A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11.55
Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov (2007) 11.46
Tumor angiogenesis. N Engl J Med (2008) 11.30
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
Mesenchymal stem cells in health and disease. Nat Rev Immunol (2008) 11.14
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet (2007) 11.06
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature (2009) 10.31
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 10.06
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Primary bioassay of human tumor stem cells. Science (1977) 9.69
Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med (1995) 9.02
Identification of cells initiating human melanomas. Nature (2008) 8.28
The stem-cell niche as an entity of action. Nature (2006) 7.73
Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature (2006) 7.69
Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol (1999) 7.66
Asymmetric and symmetric stem-cell divisions in development and cancer. Nature (2006) 7.32
Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell (2009) 7.09
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell (2007) 7.05
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Dynamics of chronic myeloid leukaemia. Nature (2005) 6.63
Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell (2008) 6.48
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res (2007) 6.21
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell (2004) 5.98
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 5.96
Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med (2006) 5.92
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature (2008) 5.59
Characterization of clonogenic multiple myeloma cells. Blood (2003) 5.35
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol (2007) 5.21
Cancer stem cells: mirage or reality? Nat Med (2009) 5.20
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov (2009) 4.12
Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One (2008) 3.97
Biological diversity in metastatic neoplasms: origins and implications. Science (1982) 3.95
Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer (2003) 3.93
Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A (2009) 3.87
Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature (2008) 3.82
Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res (2006) 3.81
Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer (2007) 3.80
PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008) 3.75
A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature (2008) 3.74
Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res (2005) 3.74
In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res (2008) 3.66
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res (2005) 3.52
CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer (2008) 3.46
Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature (2009) 3.37
Vasculogenic mimicry and tumor angiogenesis. Am J Pathol (2000) 3.19
Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ (2006) 3.12
Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med (2007) 3.02
Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res (2008) 2.97
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood (2001) 2.71
Characterization of acute lymphoblastic leukemia progenitor cells. Blood (2004) 2.65
Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell (2009) 2.60
In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst (2009) 2.39
Increased expression of stem cell markers in malignant melanoma. Mod Pathol (2006) 2.39
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med (2005) 2.36
Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst (1971) 2.17
Identification of cancer stem cells in Ewing's sarcoma. Cancer Res (2009) 2.15
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood (2007) 2.14
Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res (2004) 2.10
A QUANTITATIVE ASSAY FOR THE NUMBER OF MURINE LYMPHOMA CELLS CAPABLE OF PROLIFERATION IN VIVO. Nature (1963) 1.96
Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res (2000) 1.94
Bmp4 signaling is required for outflow-tract septation and branchial-arch artery remodeling. Proc Natl Acad Sci U S A (2004) 1.93
Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol (2004) 1.87
Vasculogenic mimicry. APMIS (2004) 1.76
The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells (2008) 1.70
Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res (2008) 1.65
Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst (2004) 1.49
Identification of cells initiating human melanomas. Nature (2008) 8.28
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res (2005) 3.52
Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem (2003) 2.10
Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res (2010) 1.83
Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res (2008) 1.65
VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res (2011) 1.62
The in vitro spheroid melanoma cell culture assay: cues on tumor initiation? J Invest Dermatol (2010) 1.53
Identification and targeting of cancer stem cells. Bioessays (2009) 1.44
Regulation of myogenic progenitor proliferation in human fetal skeletal muscle by BMP4 and its antagonist Gremlin. J Cell Biol (2006) 1.42
Antitumor immunity and cancer stem cells. Ann N Y Acad Sci (2009) 1.36
The pro-apoptotic protein Bim is a microRNA target in kidney progenitors. J Am Soc Nephrol (2011) 1.27
ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res (2011) 1.23
Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun (2010) 1.13
Synergy of photoacoustic and fluorescence flow cytometry of circulating cells with negative and positive contrasts. J Biophotonics (2012) 1.05
Tumor dormancy and cancer stem cells: two sides of the same coin? Adv Exp Med Biol (2013) 1.04
SOX2 and nestin expression in human melanoma: an immunohistochemical and experimental study. Exp Dermatol (2011) 1.01
Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity. J Invest Dermatol (2011) 0.96
Tumor initiation in human malignant melanoma and potential cancer therapies. Anticancer Agents Med Chem (2010) 0.88
CD40-induced transcriptional activation of vascular endothelial growth factor involves a 68-bp region of the promoter containing a CpG island. Am J Physiol Renal Physiol (2004) 0.87
Colorectal Cancer Stem Cells: Biology and Therapeutic Implications. Curr Colorectal Cancer Rep (2011) 0.87
A novel in vivo regulatory role of P-glycoprotein in alloimmunity. Biochem Biophys Res Commun (2010) 0.86
Genetically determined ABCB5 functionality correlates with pigmentation phenotype and melanoma risk. Biochem Biophys Res Commun (2013) 0.86
ABCB5 gene amplification in human leukemia cells. Leuk Res (2009) 0.84
The multidrug-resistance transporter ABCB5 is expressed in human placenta. Int J Gynecol Pathol (2014) 0.78
P-glycoprotein and alloimmune T-cell activation. Clin Appl Immunol Rev (2003) 0.76